|
|
|
| Clinical significance of soluble tumorigenic source 2 and brain natriuretic peptide in the diagnosis of heart failure with preserved ejection fraction |
| GUO Xiao1 WANG Xiaolong2 TANG Renzhi1 SUN Yuanlong2 LI Yiping1 XIAO Zhengda1 RUAN Xiaofen2 |
1.Department of Geriatric Medicine, Shanghai Yingkang Nursing Hospital, Shanghai 201712, China;
2.Department of Cardiovascular, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China |
|
|
|
Abstract The prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing. HFpEF is characterized by increased left ventricular diastolic blood pressure, and pathophysiological changes are myocardial hypertrophy, progressive myocardial fibrosis, and increased myocardial cell hardness. Myocardial fibrosis is closely related to HFpEF. At present, HFpEF diagnostic criteria are still controversial and used to mainly rely on echocardiographic to evaluate left ventricular diastolic sfunction and filling pressure. In recent years, studies have found that the sensitivity and specificity of brain natriuretic peptide and soluble tumorigenic source2 (sST2) are satisfactory in the diagnosis of HFpEF. This review starts with myocardial fibrosis and its detection methods and discusses the changes and significance of sST2 in HFpEF patients, the diagnostic value, prognostic judgment and clinical guidance of sST2 combined with BNP for HFpEF.
|
|
|
|
|
|
[1] Yancy CW，Essup M，et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America [J]. Circulation，2016，134（13）：e298.
[2] Ponikowski P，Voors AA，Anker SD，et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [J]. Eur J Heart Fail，2016，18（8）：891-975.
[3] Paulus WJ，Tsch?觟pe C，Sanderson JE，et al. How to diagnose diastolic heart failure：a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology [J]. Eur Heart J，2007，28（20）：2539-2550.
[4] Thomas L，Marwick TH，Popescu BA，et al. Left Atrial Structure and Function，and Left Ventricular Diastolic Dysfunction：JACC State-of-the-Art Review [J]. J Am Coll Cardiol,2019，73（15）：1961-1977.
[5] McMurray JJ，Adamopoulos S，Anker SD，et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012：The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC [J]. Eur J Heart Fail，2012，14（14）：803-869.
[6] Oghlakian GO，Sipahi I，Fang JC. Treatment of Heart Failure With Preserved Ejection Fraction： Have We Been Pursuing the Wrong Paradigm? [J]. Mayo Clinic Proc，2011， 86（6）：531-539.
[7] Metra M. June 2016 at a glance：epidemiology，renal impairment，heart failure with preserved ejection fraction [J]. Eur J Heart Fail，2016，18（6）：587.
[8] Primessnig U，Sch?觟nleitner P，H?觟ll A，et al. Novel pathomechanisms of cardiomyocyte dysfunction in a model of heart failure with preserved ejection fraction [J]. Eur J Heart Fail，2016，18（8）：987-997.
[9] 吴宏，郑亮，田才林，等.上海市高行老年社区射血分数保留的心力衰竭危险因素分析[J].中国医药导报，2018， 15（15）：51-53，64.
[10] Lam CS，Donal E，Kraigher-Krainer E，et al. Epidemiology and clinical course of heart failure with preserved ejection fraction [J]. Eur J Heart Fail，2011，13（1）：18-28.
[11] Paulus WJ，Tsch?觟pe C. A Novel Paradigm for Heart Failure With Preserved Ejection Fraction：comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation [J]. J Am Coll Cardiol，2013，62（4）：263-271.
[12] Lewis GA，Schelbert EB，Williams SG，et al. Biological Phenotypes of Heart Failure With Preserved Ejection Fraction [J]. J Am Coll Cardiol，2017，70（17）：2186-2200.
[13] van Heerebeek L，Paulus WJ. Understanding heart failure with preserved ejection fraction：where are we today? [J]. Neth Heart J，2016，24（4）：227-236.
[14] Zile MR，Baicu CF，Ikonomidis JS，et al. Myocardial Stiffness in Patients With Heart Failure and a Preserved Ejection Fraction：Contributions of Collagen and Titin [J]. Circulation，2015，131（14）：1247-1259.
[15] Schelbert EB，Fridman Y，Wong TC，et al. Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction：Association With Baseline Disease Severity and Subsequent Outcome [J]. JAMA Cardiol，2017，2（9）：995-1006.
[16] Berezin AE. Prognostication in Different Heart Failure Phenotypes：The Role of Circulating Biomarkers [J]. J Circ Biomark，2016，5：6.
[17] Zile MR，Baicu CF. Biomarkers of Diastolic Dysfunction and Myocardial Fibrosis：Application to Heart Failure with a Preserved Ejection Fraction [J]. J Cardiovasc Transl Res，2013，6（4）：501-515.
[18] 高婉琴，李小丹，杨朋康，等.血清Galectin-3和sST2水平检测用于保留射血分数心力衰竭的生物标记物的研究[J].现代检验医学杂志，2019，34（6）：54-59.
[19] Michalska-Kasiczak M，Bielecka-Dabrowa A，von Haehling S，et al. Biomarkers，myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction：an overview [J]. Arch Med Sci，2018，14（4）：890-909.
[20] Pascual-Figal DA， Ordoez-Llanos J，Tornel PL，et al. Soluble ST2 for Predicting Sudden Cardiac Death in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction [J]. J Am Coll Cardiol，2009，54（23）：2174-2179.
[21] Palmer SC，Yandle TG，Nicholls MG，et al. Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma [J]. Eur J Heart Fail，2014，11（9）：832-839.
[22] 申岩，高瑞敏，康玲玲，等.脑钠肽在心力衰竭中的研究进展[J].中国医药导报，2017，14（32）：35-38.
[23] Shah KB，Kop WJ，Christenson RH，et al. Prognostic Utility of ST2 in Patients with Acute Dyspnea and Preserved Left Ventricular Ejection Fraction [J]. Clin Chem，2011，57（6）：874-882.
[24] Seki K，Sanada S，Kudinova AY，et al. Interleukin-33 Prevents Apoptosis and Improves Survival After Experimental Myocardial Infarction Through ST2 Signaling [J]. Circ Heart Fail，2009，2（6）：684-691.
[25] Sabatine MS，Morrow DA，Higgins LJ，et al. Complementary Roles for Biomarkers of Biomechanical Strain ST2 and N-Terminal Prohormone B-Type Natriuretic Peptide in Patients With ST-Elevation Myocardial Infarction [J]. Circulation，2008，117（15）：1936.
[26] Demyanets S，Kaun C，Pentz R，et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in humancardiac cells and in cells of the cardiac vasculature [J]. J Mol Cell Cardiol，2013，60：16-26.
[27] 合力切木·艾麦尔，艾力曼·马合木提.慢性心力衰竭与血清可溶性ST2的相关性研究进展[J].医学综述，2016，22（8）：1474-1477.
[28] 合力切木·艾麦尔.慢性心力衰竭与血清可溶性ST2的相关性研究[D].乌鲁木齐：新疆医科大学，2016.
[29] 韩冰，李妮，聂荷香，等.心力衰竭患者血清中可溶性ST2和脑钠肽相关性分析[J].标记免疫分析与临床，2015， 22（1）：4-6.
[30] Yancy CW，Jessup M，Bozkurt B，et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [J]. J Am Coll Cardiol，2013，62（16）：e147-e239.
[31] 王霞，张秀明.可溶性ST2在心力衰竭中的临床应用前景[J].国际检验医学杂志，2015，36（3）：387-389.
[32] 袁帅，李佳.ST2在心力衰竭诊断及预后中的应用[J].中国心血管杂志，2016，21（5）：409-412.
[33] Pellman J，Zhang J，Sheikh F. Myocyte-Fibroblast Communication in Cardiac Fibrosis and Arrhythmias：Mechanisms and Model Systems [J]. J Mol Cell Cardiol，2016， 94：22-31.
[34] 李珊珊，高蓉蓉，张海锋，等.sST2和半乳糖凝集素3对急性心力衰竭短期预后的预测价值[J].江苏医药，2016， 42（4）：402-404.
[35] 李吉博，安娜，王佳，等.可溶性ST2联合NT-proBNP评估射血分数保留性心力衰竭患者的短期预后价值[J].岭南心血管病杂志，2018，24（2）：75-78，109.
[36] Morrow DA，Velazquez EJ，DeVore AD，et al. Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial [J]. Eur Heart J，2019，40（40）：3345-3352.
[37] Manzano-Fernández S，Mueller T，Pascual-Figal D，et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction [J]. Am J Cardiol，2011，107（2）：259-267.
[38] Aimo A，Vergaro G，Passino C，et al. Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure：A Meta-Analysis [J]. JACC Heart Fail，2017，5（4）：280-286.
[39] Zile MR，O′Meara E，Claggett B，et al. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HfrEF [J]. J Am Coll Cardiol，2019，73（7）：795-806.
[40] 黄桂锋.可溶性ST2及NT-proBNP在心力衰竭中的变化和临床意义[J].中国当代医药，2015，22（9）：131-133. |
|
|
|
